AIM vs. MIRA, THAR, CVKD, FBLG, ALLR, PMN, ENLV, NAII, NEUP, and RLYB
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include MIRA Pharmaceuticals (MIRA), Tharimmune (THAR), Cadrenal Therapeutics (CVKD), FibroBiologics (FBLG), Allarity Therapeutics (ALLR), Promis Neurosciences (PMN), Enlivex Therapeutics (ENLV), Natural Alternatives International (NAII), Neuphoria Therapeutics (NEUP), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry.
AIM ImmunoTech vs. Its Competitors
MIRA Pharmaceuticals (NASDAQ:MIRA) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
In the previous week, AIM ImmunoTech had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for AIM ImmunoTech and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.00 equaled AIM ImmunoTech'saverage media sentiment score.
MIRA Pharmaceuticals has higher earnings, but lower revenue than AIM ImmunoTech. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
MIRA Pharmaceuticals currently has a consensus target price of $17.00, indicating a potential upside of 1,105.67%. AIM ImmunoTech has a consensus target price of $275.00, indicating a potential upside of 10,600.39%. Given AIM ImmunoTech's higher probable upside, analysts plainly believe AIM ImmunoTech is more favorable than MIRA Pharmaceuticals.
MIRA Pharmaceuticals has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. MIRA Pharmaceuticals' return on equity of -406.70% beat AIM ImmunoTech's return on equity.
35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
MIRA Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.
Summary
MIRA Pharmaceuticals beats AIM ImmunoTech on 10 of the 15 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
This page (NYSE:AIM) was last updated on 9/10/2025 by MarketBeat.com Staff
Free AIM Stock Alerts